A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2017
At a glance
- Drugs Tremelimumab (Primary)
- Indications Colorectal cancer; Malignant melanoma; Prostate cancer; Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca; MedImmune; Pfizer
- 15 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 15 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 01 May 2016 This study is discontinued in Italy as per European Clinical Trials Database record.